Yanqiao Zhang

24PUBLICATIONS
133CO-AUTHORS
ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Aug 24, 2026
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study.

|Jul 16, 2026
Elevated CHAF1A suppresses type I interferon production and causes immunotherapy resistance in esophageal squamous cell carcinoma.

|Oct 30, 2025
A Robust Immunohistochemistry-Based Classification for BRAF V600E-Mutant Colorectal Cancer With Clinical Implications.

Chao Liu, Yuli Ruan, Tong Wu

|May 16, 2025
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study.

Ningning Zhang, Tian Liu, Ming Luo

|May 05, 2025
USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment.

Shuling Han, Luying Cui, Bojun Wang

|Jan 24, 2025
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.

Sun Young Rha, Yanqiao Zhang, Anneli Elme

Pageof 4

Frequent Collaborators

6 joint publications

Chao Liu

4 joint publications

Bojun Wang

3 joint publications

Luying Cui

3 joint publications

Yuanyu Liao